DiGA Attexis: Digital support for adults with ADHD

According to the Federal Institute for Drugs and Medical Devices (BfArM), Attexis is a DiGA for patients with ADHD who are at least 18 years old. It teaches methods and techniques of cognitive behavioral therapy. The app is customizable and includes planning functions and checklists to facilitate daily structuring.

A randomized controlled trial with 337 participants showed that three months after using Attexis in addition to usual medical care, those affected had fewer ADHD symptoms than those who received only usual medical care. Self-esteem, social and occupational functioning, and depressive symptoms also improved.

The product from Gaia costs €599.40. Since August 6, 2025, all health insurance companies and many private health insurers have covered the costs. According to the manufacturer, Attexis is the first permanently approved app for adults with ADHD as a DiGA.

The program is intended for self-administration only. Doctors or psychotherapists are therefore not required to provide additional services such as coaching when prescribing Attexis. The app can, but does not have to, be combined with other therapies.

Only recently, the DiGA hiToco from Medigital was launched for parents of Children with ADHD are provisionally included in the DiGA directory of the BfArM (Federal Institute for Drugs and Medical Devices). It is a parent training program that includes psychoeducational content and elements of cognitive behavioral therapy. Its use is intended to enable parents and other guardians to adapt their parenting behavior together with their child in an interactive way.

Also provisionally included is the Oriko ADHD Therapy DiGA from Mindnet e-Health Solutions, which is aimed at adults with ADHD. According to the BfArM (Federal Institute for Drugs and Medical Devices), the application is designed to improve quality of life and ADHD symptoms, as well as disease-related everyday problems. It is intended to increase health literacy and reduce secondary disorders such as anxiety and depression. The program is designed for twelve weeks, during which users work through psychotherapeutic content independently, also with the help of multimedia and interactive content.

Both provisionally listed applications are currently undergoing testing and must provide evidence of effectiveness within one year.